Developing an Opioid Taper Intervention Before Total Joint Arthroplasty

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Alabama at Birmingham

About this trial

The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are:

* Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period?

Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.

Eligibility criteria

Qualifiers

decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks

currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months

have a reliable telephone number for contact

speaks English

Disqualifiers

Buprenorphine

Methadone

Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine)

Transdermal formations of opioid pain medications (e.g., fentanyl patches)

Trial design

Treatments tested in this trial

  • opioid taper

Treatment groups

45 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Alabama at Birmingham

Lead sponsor

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Collaborator